According to the U.S. Census Bureau, more than 34.6 million adults ages 18 and above do not have a high school diploma. In an effort to combat this critical issue, the Ad Council and the Dollar General Literacy Foundation joined today to launch new public service advertisements (PSAs) on behalf of their national GED Achievement campaign. This multimedia campaign is designed to provide high school dropouts the encouragement and information needed to begin the road to a GED diploma.
Recent data shows that students who drop out of high school tend to earn less and have a lower quality of life. Many of them must work multiple jobs just to support their family. Moreover, as of 2009, nearly 30% of adults with household incomes at or below the federal poverty line did not have a high school credential.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55571-ad-council-dollar-general-literacy-foundation-your-ged-pep-talks-psa
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/pvct/43978/
Summer is the hottest season of the year for vehicle theft, with July and August ranking as the highest auto theft months of the year, and July 4th in particular ranking #3 (latest FBI data) on the list of holidays with the highest incidents of vehicle theft. Vehicle theft protection experts warn that consumers are growing increasingly complacent about auto theft and are not using even common sense measures to protect their vehicles from theft.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/lojack/50795/
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
Personalised Medicine is the future of cancer treatment, but it presents major challenges for doctors and health services, the President of the European Society of Medical Oncology has said. Professor Rolf Stahel was speaking ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430351-professor-rolf-stahel-astellas-debate/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
To view the multimedia release go to:
http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
International treatment guidelines – from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) – have advised that prevention of exacerbations should be a cornerstone of COPD management, placing equal emphasis on the management of future risk as it does on treatment of COPD symptoms.1 This is also confirmed in the latest data on the impact of season on the frequency of COPD exacerbations, showing an almost two-fold increase in the winter months. This is contributing to the increased morbidity seen during the festive season.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/nycomedtakeda/52782/
For the tenth consecutive year, silver has ranked as the most popular vehicle color in the world according to data from PPG Industries (NYSE:PPG), the world’s leading manufacturer of transportation coatings. In fact, silver’s popularity is the highest its been since 1990 when PPG began recording its data.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/ppg/46056/
Potash Corporation of Saskatchewan Inc. (“PotashCorp”) today launched potashcorp-eKonomics.com, a new online resource that delivers easy-to-understand analyses of soil science data, agronomic information, research and best management practices to help farmers achieve greater financial success. As part of a larger campaign, the site aims to educate farmers about the benefits fertilizer – specifically potash – can deliver to their bottom line.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61611-potashcorp-launches-ekonomics-business-of-soil-fertility
Planetary Resources, Inc., the asteroid mining company, announced today that it has secured US$21.1 million in Series A funding. The capital will be used to deploy and operate Ceres, an advanced Earth observation business that features the first commercial infrared and hyperspectral sensor platform to better understand and manage humanity’s natural resources. The funding was led by Bryan Johnson and the OS FUND; and joined by Idea Bulb Ventures; Tencant; Vast Ventures; Grishin Robotics; Conversion Capital; The Seraph Group; Space Angels Network, a syndication of investors from Angel.co; and Larry Page. Earth observation will be another aspect of Planetary Resources’ operations in addition to prospecting and mining asteroids.
Conceived from the company’s vision for the exploration and utilization of asteroid resources, Ceres will leverage Planetary Resources’ Arkyd spacecraft to deliver affordable, on-demand Earth intelligence of our natural resources on any spot on the planet. While typical satellite imagery provides only a picture, Ceres will provide actionable data with higher spectral resolutions – going beyond what the human eye can see – by measuring thermographic properties and detecting the composition of materials on Earth’s surface. The midwave-infrared sensor is the first ever commercial capability from space to offer thermographic mapping and night-imaging, and the hyperspectral sensor includes an unprecedented 40 color bands in the visible to near-infrared spectrum.
To view the multimedia release go to:
http://www.multivu.com/players/English/7847251-planetary-resources-ceres/
